NVO Oct 2023 110.000 call
| Previous close | 65.00 |
| Open | 65.00 |
| Bid | 58.80 |
| Ask | 63.60 |
| Strike | 110.00 |
| Expiry date | 2023-10-20 |
| Day's range | 65.00 - 65.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
ZacksBrokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Motley FoolBetter Dividend Stock: Eli Lilly or Novo Nordisk?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
Globe NewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 30 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiate
Motley FoolThis Pharma's Sales Are So Hot It's Trying to Curb Demand
Novo Nordisk (NYSE: NVO) is planning to pause some of its advertising campaigns for its obesity drug Wegovy, due to white-hot demand in the U.S. The impact of the move isn't the marketing costs it saves, but the unambiguous message it sends: Wegovy is probably going to bring in even more sales than management expected -- and it had expected quite a bit. This isn't the first time that demand for Wegovy has been greater than what the pharma can manufacture, and it's no surprise why.
ZacksNovo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Yahoo Finance VideoPfizer weight loss drug may be as effective as competitors: Study
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
ZacksHere's Why Novo Nordisk (NVO) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Globe Newswire
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion for expanded use in children and adolescents with growth hormone deficiency
Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya® (somapacitan) for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. Symptoms of growth hormone deficiency in children often start early in life, leading to short stature
ZacksTime to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
ZacksNovo Nordisk (NVO) Collaborates for Gene-Editing Therapies
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
ZacksIs Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
- Globe Newswire
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk
Motley FoolWhy Novo Nordisk Stock Is Falling Today
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.
ZacksNovo Nordisk (NVO) Announces Positive Obesity Program Data
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
ZacksBristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
ZacksPfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Yahoo Finance VideoPfizer stock rises on positive results from weight loss drug study
Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.
- Zacks
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
- Globe Newswire
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities. Both treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and sup
ZacksTake the Zacks Approach to Beat the Market: Shopify, Brambles, McDonald's in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
ZacksNovartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Motley FoolIf You Invested $10,000 in Novo Nordisk in 2020, This Is How Much You Would Have Today
Novo Nordisk (NYSE: NVO) is the company behind diabetes and weight-loss treatments Ozempic and Wegovy. Business has been booming as demand for those drugs has left the company in a rush to add capacity so that it can fill orders. On Jan. 2, 2020, shares of Novo Nordisk opened at a price of $58.31.
ZacksHere's Why Merck (MRK) Stock Has Outperformed Industry YTD
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
